Results 131 to 140 of about 113,181 (243)

Improved Safety of Nucleic Acid Amplification Technology Combined With Serological Tests for Screening Blood Donors: A Systematic Review and Meta-Analysis. [PDF]

Rev Med Virol
Madeira HS, Brustolin AÁ, Almeida MEDS, Ribeiro MVG, Aguera RG, Jorge FA, Ghiraldi LD, Moreira DC, Lonardoni MVC, Bertolini DA, Peder LD, Silva CMD, Lera-Nonose DSSL, Ramos-Milaré ÁCFH, Teixeira JJV.   +14 more
europepmc   +1 more source

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Novel Long-Read Sequencing Method for Characterisation of Hepatitis B Transcripts Show High Expression of Chimeric HBV/Human RNA. [PDF]

Liver Int
Stenbäck JB, Ringlander J, Andersson M, Thomsen JHD, Abrahamsson S, Rydell GE, Lindh M.   +6 more
europepmc   +1 more source

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis

Hepatology Research, EarlyView.
The platelet count can be used to predict liver function at the time of evaluation of progressive disease (PD) after atezolizumab plus bevacizumab (ATZ/BEV) therapy in patients with u‐HCC. Treatment strategies in u‐HCC patients with low platelet counts should be conducted by taking into account deterioration of liver function after ATZ/BEV.
Ryo Sato, Takanori Suzuki, Kentaro Matsuura, Daisuke Kato, Katsumi Hayashi, Kohei Okayama, Fumihiro Okumura, Satoshi Sobue, Atsunori Kusakabe, Izumi Hasegawa, Kiyoto Narita, Tsutomu Mizoshita, Yoshihide Kimura, Hiromu Kondo, Hisayo Kojima, Kazuki Hayashi, Atsushi Ozasa, Hayato Kawamura, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Sakurayama Liver Study Group (SLSG)   +21 more
wiley   +1 more source

The Hepatic Steatosis Diagnostic Performance Using Attenuation Imaging With the Magnetic Resonance Imaging‐Based Proton Density Fat Fraction as the Reference Standard: A Large, Prospective, Multicenter Cohort Study in Japan

Hepatology Research, EarlyView.
In a multicenter cohort of 1059 patients, attenuation imaging (ATI) showed good diagnostic performance and strong correlation with MRI‐PDFF, supporting its value as a noninvasive method for evaluating hepatic steatosis. ABSTRACT Background Attenuation imaging (ATI) is used for the noninvasive diagnosis of hepatic steatosis (HS) based on the ultrasound ...
Takashi Nishimura, Hiroko Iijima, Yasuaki Suzuki, Kent Imajo, Tamami Abe, Hidekatsu Kuroda, Masashi Hirooka, Asako Nogami, Sadanobu Ogawa, Satoshi Oeda, Katsutoshi Sugimoto, Toshifumi Tada, Reiichiro Kondo, Tomoyuki Akita, Shigehiro Kokubu, Yoichi Hiasa, Atsushi Nakajima, Hidenori Toyoda, Hirokazu Takahashi, Yuichiro Eguchi, Hirohisa Yano, Junko Tanaka, Fuminori Moriyasu, Masayoshi Kage, Takashi Kumada   +24 more
wiley   +1 more source

Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights. [PDF]

Liver Int
Franzè MS, Pollicino T, Pawlotsky JM, Leroy V, Raimondo G, Amaddeo G.   +5 more
europepmc   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial. [PDF]

J Viral Hepat
Luo Q, Xu W, Zhang Y, Li X, Lai J, Li J, Zheng X, Deng H, Chen L, Zhu X, Xie C, Peng L.   +11 more
europepmc   +1 more source

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Background Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline
Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Hideki Onishi, Miwa Kawanaka, Akinobu Takaki, Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, Emi Tanaka, Toshifumi Tada, Tetsuya Yasunaka, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Masahiro Sakata, Motoyuki Otsuka   +20 more
wiley   +1 more source

Knowledge, Attitude, and Practices Towards Hepatitis B Infection Among Nursing Students: A Cross-Sectional Study in Jordan. [PDF]

Health Sci Rep
Alaridah N, Jarrar RF, Joudeh RM, Aljarawen M, Nassr H, Jereisat RA, Battah A, Jum'ah M, Hantash NRA, Amr MN, Al-Abdallat H, Ismail L, El-Massad AY, Mahmmoud H, Abu-Humaidan AHA.   +14 more
europepmc   +1 more source